Global Healthcare Group
The Best Partner for You
About Daewoong
Affiliates
Holding Company
-
- Daewoong
- Resource management and management support for affiliated companies
- Go to homepage
Daewoong Affiliates
-
- Daewoong Pharmaceutical
- Manufacture and sales of finished dose
- Go to homepage
-
- Daewoong Bio
- Manufacture and sales of API
- Go to homepage
-
- Daewoong Life Science
- Production and sales of health food and life products
- Go to homepage
-
- DMD Daewoong Management Development Institute
- Corporate personnel training business
- Go to homepage
-
- idsTrust
- Computer, peripheral devices and software development and sales
- Go to homepage
-
- Daewoong ENG
- Facility management services and machine production
- Go to homepage
-
- Daewoong Development
- Real estate leasing
-
- Daewoong Therapeutics
- R&D on first-in-class DR/DDS-based new drugs
- Go to homepage
-
- Daewoong pet
- Manufacture and sales of veterinary medicine
- Go to homepage
Daewoong Pharmaceutical Affiliates
-
- Hanall Biopharma
- Pharmaceutical product R&D
- Go to homepage
-
- MD Well
- Medicine and nutrition company, production and sales of nutritious meals
- Go to homepage
-
- Seonmaeul
- New conceptual lifestyle improvement program, and the nation’s first wellness center
- Go to homepage
-
- Affyxell Therapeutics
- R&D on pharmaceutical drugs and medicine
- Go to homepage
-
- iN Therapeutics
- R&D on pharmaceutical drugs and medicine
- Go to homepage
-
- DaNaA Data
- Big Data / AI-based healthcare business
- Affyxell Therapeutics
- R&D on pharmaceutical drugs and medicine
History
from intractable disease and regain their health.
- DW transfers the platform license and technology
- DW provides DW-MSC production know-how
- DW’s MSC development experts (R&D/RA/CMC/Clinical)
- Affimer performs development and tech transfer
- Affimer transfers specific target exclusive IP
- Affimer’s development experts (R&D/Clinical)
Limit 1.
Limitations of Current Stem Cell Therapy
-
Donor
variance -
High cost
Low efficacy -
Need for
specific MoA
Limit 2.
Limitations of Current Non-IgG Scaffold
-
Relatively short
Half-life
compared to
Antibody drugs -
Low efficacy
Compared to
Competitive
treatments -
Lack of feasible
New substance
AFX platform : Affimer-encoded Mesenchymal Stem Cells
Overcoming Barriers
Next Generation Cell Therapy (AFX Platform)
① Overcoming donor variance by using pluripotent
stem cell-derived MSC
② Improved productivity in cell therapy by using pluripotent
stem cell-derived MSC
③ Securing specific treatment mechanism through
Affimer gene introduction
④ Synergy through platform convergence
In-body factory : overcoming a short half-life of Affimer Superior efficacy expected compared to
competitor treatments
*Pluripotent stem cell-derived Mesenchymal Stem Cell